Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms

Sydney X. Lu, MD PhD, Eric Wang, Alessandro Pastore, Chen Xufeng, PhD, Jochen Imig, PhD, Stanley C Lee, PhD, Yohana Ghebrechristos, Akihide Yoshimi, MD, Lillian E Bitner, BSc, Michelle Ki, BSc, Andreas Kloetgen, Kuan-Ting Lin, PhD, Raoul Tibes, MD PhD, Adrian R. Krainer, PhD, Taisuke Uehara, Takashi Owa, PhD, Iannis Aifantis, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 427.

https://doi.org/10.1182/blood-2018-99-111430

Published: 2018

Journal Articles

RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models

Yi-Jou Huang, BS, Ming Yan, PhD, Jia-Yu Chen, PhD, Liang Chen, PhD, Eunhee Kim, PhD, Takahiro Shima, MD PhD, Amanda G Davis, BS, Sayuri Miyauchi, DDS, PhD, Samuel A Stoner, Xiang-Dong Fu, PhD, Omar I Abdel-Wahab, MD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2018-99-119104

Published: 2018

Journal Articles

Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors

Justin Taylor, MD, Mark Donoghue, PhD, Raajit K. Rampal, MD PhD, Roni Tamari, MD, Martin S. Tallman, MD, Darren R. Feldman, MD, Barry S Taylor, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 87.

https://doi.org/10.1182/blood-2018-99-111976

Published: 2018

Journal Articles

Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization

Akihide Yoshimi, MD, Zhaoqi Liu, PhD, Wang Jiguang, Hana Cho, MSc, Stanley C Lee, PhD, Michelle Ki, BSc, Lillian E Bitner, BSc, Timothy Chu, Anthony R Mato, MD, Peter P. Ruvolo, PhD, Giulia Fabbri, Laura Pasqualucci, MD, Raul Rabadan, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 882.

https://doi.org/10.1182/blood-2018-99-110328

Published: 2018

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Leukemia Risk Gene ARID5B is a Crucial Regulator of B-Cell Development

Charnise Goodings-Harris, PhD, Hui Zhang, PhD, Xuijie Zhao, Heng Xu, PhD, Omar I Abdel-Wahab, MD, Shannon McKinney-Freeman, PhD, Jun J. Yang, PhD

Blood (2018) 132 (Supplement 1): 385.

https://doi.org/10.1182/blood-2018-99-113686

Published: 2018

Journal Articles

High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations

Anna S Nam, MD, Kyu-Tae Kim, PhD, Ronan Chaligne, PhD, Franco Izzo, PhD, Chelston Ang, MS, Nathaniel Omans, MS, Alessandro Pastore, Justin Taylor, MD, Alicia Alonso, Wayne Tam, MD PhD, Ronald Hoffman, MD, Joseph Scandura, MDPhD, Raul Rabadan, PhD, Omar I Abdel-Wahab, MD, Peter Smibert, PhD, Dan A. Landau, MD PhD

Blood (2018) 132 (Supplement 1): 541.

https://doi.org/10.1182/blood-2018-99-119236

Published: 2018

Journal Articles

Dependency of Spliceosomal Mutant MDS on Innate Immune Signaling

Stanley C Lee, PhD, Khrystyna North, Chi-Chao Chen, Eunhee Kim, PhD, Sydney X. Lu, MD PhD, Michelle Ki, BSc, Ralph Garippa, PhD, Scott W Lowe, PhD, Robert K. Bradley, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 937.

https://doi.org/10.1182/blood-2018-99-111552

Published: 2018

Journal Articles

Specific Bone Marrow Mesenchymal Subsets in Patients with Myelodysplastic Syndromes Harbor Molecular Perturbations That Alter the Dynamics of Competition between Pre-Leukemic Clones and Normal Cells

Youmna Kfoury, PhD, Esha Jain, Jason R Myers, MS, Fei Ji, David B Sykes, MD PhD, Francois Mercier, MD FRCPC, Ani Papazian, BS, Cam Le, Mark A Randolph, M.A.Sc., David P. Steensma, MD, Omar I Abdel-Wahab, MD, Laura M. Calvi, MD, Ruslan I Sadreyev, PhD, Michael W. Becker, MD, David T. Scadden, MD

Blood (2018) 132 (Supplement 1): 938.

https://doi.org/10.1182/blood-2018-99-115242

Published: 2018

Journal Articles

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Ran Weissman, MSc, Nir Pilar, MD, Benjamin H Durham, MD BS, Michelle Ki, BSc, Roei D Mazor, MD, Omar I Abdel-Wahab, MD, Noam Shomron, PhD, Ofer Shpilberg, MD MPH, Eli L Diamond, MD, Oshrat Rokah, PhD

Blood (2018) 132 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2018-99-112388

Published: 2018

Journal Articles

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Benjamin H Durham, MD BS, Estibaliz Lopez-Rodrigo, MD, David H Abramson, MD, Jennifer Picarsic, MD, Alessandro Pastore, Diana Mandelker, MD PhD, Michael Francis Walsh, MD, Maria E Arcila, MD, Marc Ladanyi, MD, David Solit, MD, Michael F. Berger, PhD, David M. Hyman, MD, Michelle Ki, BSc, Ira Dunkel, MD, Frederic Geissmann, MD PhD, Eli L Diamond, MD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 49.

https://doi.org/10.1182/blood-2018-99-114248

Published: 2018

Journal Articles

Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution

Ronan Chaligne, PhD, Federico Gaiti, PhD, Franco Izzo, PhD, Steven Kothen-Hill, MS, Hongcang Gu, Kevin Huang, BS, Davide Risso, PhD, Rafael Schulman, BS, Ryan M Brand, Stanley C Lee, PhD, Asaf Poran, Kye-Tae Kim, PhD, Alessandro Pastore, Alicia Alonso, Andreas Gnirke, Catherine J. Wu, MD, Omar I Abdel-Wahab, MD, Alexander Meissner, PhD, Dan A. Landau, MD PhD

Blood (2018) 132 (Supplement 1): 1312.

https://doi.org/10.1182/blood-2018-99-115596

Published: 2018

Journal Articles

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Justin Taylor, MD, Morgan Coleman, MPH, Kelsey Alvarez, RN, Janine Pichardo, Filiz Sen, MD, Stephen S. Chung, MD, Raajit K. Rampal, MD PhD, Jae H. Park, MD, Eytan M. Stein, MD, Martin S. Tallman, MD, Omar I Abdel-Wahab, MD, Virginia M. Klimek, MD

Blood (2018) 132 (Supplement 1): 233.

https://doi.org/10.1182/blood-2018-99-113840

Published: 2018

NARROW

Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms

RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models

Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors

Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Leukemia Risk Gene ARID5B is a Crucial Regulator of B-Cell Development

High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations

Dependency of Spliceosomal Mutant MDS on Innate Immune Signaling

Specific Bone Marrow Mesenchymal Subsets in Patients with Myelodysplastic Syndromes Harbor Molecular Perturbations That Alter the Dynamics of Competition between Pre-Leukemic Clones and Normal Cells

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only